GlobalData on MSN7d
Biogen’s higher dose Spinraza under review by US and EU regulators
Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
Yahoo Finance22d
Sanofi taps Alloy Therapeutics for CNS antisense drug development
Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide ... field include Biogen’s ASO Spinraza (nusinersen) approved ...